BiotechTube

JR-171 (lepunafusp alfa)

Phase 1/2Completed
0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Mucopolysaccharidosis I

Conditions

Mucopolysaccharidosis I

Trial Timeline

Sep 1, 2020 → Aug 2, 2022

NCT ID
NCT04227600

About JR-171 (lepunafusp alfa)

JR-171 (lepunafusp alfa) is a phase 1/2 stage product being developed by JCR Pharmaceuticals for Mucopolysaccharidosis I. The current trial status is completed. This product is registered under clinical trial identifier NCT04227600. Target conditions include Mucopolysaccharidosis I.

What happened to similar drugs?

5 of 15 similar drugs in Mucopolysaccharidosis I were approved

Approved (5) Terminated (1) Active (10)
✅laronidaseSanofiApproved
✅LaronidaseSanofiApproved
✅Aldurazyme (Recombinant Human Alpha-L-Iduronidase) + Aldurazyme (Recombinant Human Alpha-L-Iduronidase) + Aldurazyme (Recombinant Human Alpha-L-Iduronidase) + Aldurazyme (Recombinant Human Alpha-L-Iduronidase)SanofiApproved
✅LaronidaseSanofiApproved
✅NaglazymeBioMarin PharmaceuticalApproved
🔄Aldurazyme (Recombinant Human Alpha-L-Iduronidase)SanofiPhase 3
🔄rhIDU (recombinant human-Alpha-L-Iduronidase) + PlaceboSanofiPhase 3

Hype Score Breakdown

Clinical
9
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT04227600Phase 1/2Completed

Competing Products

20 competing products in Mucopolysaccharidosis I

See all competitors
ProductCompanyStageHype Score
OdiparcilInventivaPhase 2
29
anakinraSwedish Orphan BiovitrumPhase 1/2
32
laronidaseSanofiApproved
43
LaronidaseSanofiApproved
43
Aldurazyme (Recombinant Human Alpha-L-Iduronidase) + Aldurazyme (Recombinant Human Alpha-L-Iduronidase)SanofiPhase 2
35
Aldurazyme (Recombinant Human Alpha-L-Iduronidase) + Aldurazyme (Recombinant Human Alpha-L-Iduronidase) + Aldurazyme (Recombinant Human Alpha-L-Iduronidase) + Aldurazyme (Recombinant Human Alpha-L-Iduronidase)SanofiApproved
43
Laronidase + Cyclosporine A (CsA) + Azathioprine (Aza)SanofiPhase 1/2
32
Aldurazyme (Recombinant Human Alpha-L-Iduronidase)SanofiPhase 3
40
rhIDU (recombinant human-Alpha-L-Iduronidase) + PlaceboSanofiPhase 3
40
Aldurazyme + Aldurazyme + placeboSanofiPhase 3
40
LaronidaseSanofiApproved
35
JR-141JCR PharmaceuticalsPhase 2/3
38
JR-441 + JR-441 + JR-441JCR PharmaceuticalsPhase 1/2
36
JR-446JCR PharmaceuticalsPhase 1/2
39
JR-171JCR PharmaceuticalsPhase 1/2
32
JR-141JCR PharmaceuticalsPhase 2
39
JR-141 + Idursulfase + JR-141 or IdursulfaseJCR PharmaceuticalsPhase 3
44
JR-141JCR PharmaceuticalsPhase 3
47
JR-141JCR PharmaceuticalsPhase 1/2
32
JR-141JCR PharmaceuticalsPhase 2/3
42